TechnologyChemogenetic Neuromodulation
Therapeutic ClassCircuit Modulation
MechanismGPCR-based Designer Receptors
Clinical StatusPreclinical / Translational
Target RegionsStriatum, STN, GPi
LigandDeschloroclozapine (DCZ)
DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) represent an emerging chemogenetic therapeutic approach for Parkinson's disease that enables precise modulation of motor circuits through pharmacological control of genetically engineered receptors. Unlike deep brain stimulation (DBS), which requires implanted electrodes, DREADDs offer a non-invasive, circuit-specific alternative for modulating the basal ganglia circuitry that becomes dysfunctional in PD.
The therapeutic concept involves expressing excitatory (hM3Dq) or inhibitory (hM4Di) DREADDs in specific nodes of the basal ganglia-thalamocortical motor circuit, then activating or suppressing these neurons systemically by administering a designer drug (typically deschloroclozapine). This allows precise temporal control of motor circuits without surgical implantation.
Parkinson's disease involves progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to:
- Increased striatal output: Enhanced activity in the direct pathway (D1-mediated) contributing to bradykinesia
- Decreased indirect pathway activity: Reduced D2-mediated signaling affecting motor initiation
- Excessive subthalamic nucleus (STN) activity: Hyperdirect pathway overdrive
- Globus pallidus internus (GPi) inhibition: Excessive tonic output to thalamus, suppressing movement
DREADDs address these circuit dysfunctions through:
- Striatal modulation: Expressing hM3Dq in D1-expressing medium spiny neurons (MSNs) to enhance direct pathway activity
- STN inhibition: hM4Di expression in subthalamic nucleus neurons to reduce hyperdirect pathway overactivity
- GPi normalization: Targeted modulation of GPi activity to restore thalamic excitation
- Cholinergic interneuron control: Modulating striatal cholinergic interneurons that influence dopamine release
flowchart TD
subgraph "Parkinsonian State"
SNc["SNc Dopaminergic<br/>Neurons"] -->|"Loss"| Str["Striatum"]
Str -->|"Excessive D1"| GPi["GPi"]
Str -->|"Reduced D2"| STN["STN"]
STN -->|"Overdrive"| GPi
GPi -->|"Excessive Output"| Thal["Thalamus"]
Thal -->|"Inhibited"|-motor["Motor Cortex"]
motor -->|"Reduced"| Musc["Muscle Output"]
end
subgraph "DREADD Therapy"
hM3Dq["hM3Dq<br/>Excitatory"] -->|"Activate D1 pathway"| Str2["Striatum"]
hM4Di["hM4Di<br/>Inhibitory"] -->|"Inhibit STN"| STN2["STN"]
end
| DREADD Variant |
G Protein |
Effect in PD Circuit |
Target Structure |
| hM3Dq |
Gq |
Excitation |
Striatal D1 MSNs, cortex |
| hM4Di |
Gi |
Inhibition |
STN, GPi, cortex |
| KORD |
Gi |
Inhibition |
Peripheral/CNS |
Studies in parkinsonian rodent models have demonstrated:
- Rotational behavior recovery: hM3Dq activation in striatum induces contralateral rotations, compensating for dopaminergic loss
- Forelimb use restoration: Improved forelimb use in cylinder test following DREADD modulation
- Gait improvement: Enhanced step length and swing duration
- Bradykinesia reduction: Decreased fall latency in catalepsy tests
| Study |
Model |
DREADD |
Outcome |
| Whittaker 2020 |
6-OHDA lesioned rats |
hM3Dq in striatum |
Improved forelimb use |
| Steiner 2022 |
MPTP mice |
hM4Di in STN |
Reduced parkinsonian signs |
| Gradin 2024 |
MPTP primates |
hM3Dq/hM4Di dual |
Restored motor function |
Striatal D1 Neuron Activation:
- Enhances direct pathway activity
- Improves motor initiation
- Reduces freezing of gait
STN Inhibition:
- Reduces excessive excitatory drive to GPi
- Decreases thalamic inhibition
- Improves Tremor and rigidity
| Challenge |
Impact |
Solution Strategy |
| Gene delivery |
Requires viral transduction |
AAV vectors, improved serotypes |
| BBB penetration |
CNO poor, DCZ moderate |
Deschloroclozapine development |
| Long-term expression |
Immune response |
Immunosuppression, non-immunogenic vectors |
| Cell-type specificity |
Off-target effects |
Cre-dependent expression |
| Clinical ligand |
Not pharmaceutical-grade |
Pharmaceutical development |
| Ligand |
Dose |
Brain Penetration |
Onset |
Duration |
| Clozapine-N-oxide (CNO) |
1-10 mg/kg |
Low |
30-60 min |
2-4 hours |
| Deschloroclozapine (DCZ) |
0.1-1 mg/kg |
High |
15-30 min |
6-12 hours |
| Compound 21 |
0.1-3 mg/kg |
High |
20-40 min |
4-8 hours |
| Feature |
DREADDs |
DBS |
Levodopa |
| Invasiveness |
Viral injection only |
Surgical implants |
Oral medication |
| Reversibility |
Yes (stop ligand) |
Yes (device off) |
Yes (washout) |
| Specificity |
Cell-type specific |
Regional |
Systemic |
| Temporal control |
Minutes |
Immediate |
Hours |
| Chronic use |
Compatible |
Implanted |
Long-term |
| Side effects |
Potential off-target |
Hardware, infection |
Dyskinesias |
¶ Research Groups and Institutions
- University of North Carolina: Dr. Bryan Roth — DREADD development and optimization
- University of Oxford: Basal ganglia circuit mapping with DREADDs
- University of Pittsburgh: PD circuit modulation studies
- Stanford University: Chemogenetic therapies for movement disorders
- Circuit Therapeutics: Developing chemogenetic therapies
- AbbVie: Neuromodulation programs
- Boston Scientific: Next-generation modulation approaches
- Improved viral vectors: Next-generation AAV for enhanced CNS transduction
- Novel ligands: Extended half-life designer drugs
- Cell-type promoters: Specific expression in target neurons
- Safety studies: Long-term expression and immune response
- Clinical trials: First-in-human DREADD therapy for PD
- Combination approaches: DREADDs with gene therapy or cell therapy
- Closed-loop systems: Responsive modulation based on neural activity
- Personalized circuits: Patient-specific targeting
¶ Adverse Effects and Safety
- Off-target modulation: Designer ligand effects at endogenous receptors
- Expression longevity: Reduced effectiveness over time
- Immune response: Antibodies against DREADD proteins
- Circuit compensation: Adaptive changes in untreated circuits
- Temporal dosing: Intermittent rather than continuous activation
- Cell-type specificity: Cre-dependent expression systems
- Novel ligands: More selective compounds with higher DREADD affinity
- Immunomodulation: Co-administration of immunosuppressants
DREADD therapy for PD remains in the preclinical research stage. No clinical trials have been initiated, and FDA approval is not expected before 2028 at the earliest. The therapy represents a transformative approach that could eventually offer a non-invasive alternative to DBS for patients with advanced PD.